Skip to main content
. 2016 Sep 6;34(32):3921–3930. doi: 10.1200/JCO.2016.66.9648

Fig 5.

Fig 5.

Change from baseline Global Health Status/Quality of Life (GHS/QoL) domain for patients with a partial response or better. Positive change indicates improved GHS/QoL. (*) P < .05 between-group differences. KRd, carfilzomib, lenalidomide, and dexamethasone; Rd, lenalidomide and dexamethasone.